Please take a few minutes to complete our short survey to help shape the future of TB treatment in children.
In 2022, the SHINE trial https://www.nejm.org/doi/full/10.1056/NEJMoa2104535?query=featured_home showed that a four‑month treatment is as effective as the standard six‑month regimen for children with non‑severe TB, informing updated WHO guidelines.
We are gathering views to understand how widely this shorter regimen is being used in practice worldwide, and to identify any barriers to its adoption. Your input will be important in highlighting gaps, informing future guidance, and ultimately improving care for children with TB.
Please access the questionnaire here: https://forms.office.com/e/WMuWkzCuMx?origin=lprLink
Thank you very much for considering taking part and for sharing your valuable experience.
The SHINE team at UCL Innovative Clinical Trials Unit (formerly the MRC Clinical Trials Unit at UCL)
Annabelle South, PhD (she/her)
Principal Research Fellow: Research Impact & Communication
CHIFA profile:
Annabelle South is Policy, Communications & Research Impact Coordinator at the MRC Clinical Trials Unit at UCL, London, UK. She is interested in paediatric health research, particularly HIV and TB. a.south AT ucl.ac.uk